[Form 4] CNS Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

CNS Pharmaceuticals, Inc. (CNSP) reported a Form 4 filing for a director covering a new stock option grant. The derivative security is an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share, expiring on November 17, 2035.

The grant was approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan. Shareholders approved the plan at the annual meeting on November 17, 2025, defined as the “Shareholder Approval Date.” The options vest in four equal quarterly installments starting on the Shareholder Approval Date, contingent on the reporting person’s continued employment. After this transaction, the reporting person beneficially owns 1,517 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cockroft Bettina M.

(Last) (First) (Middle)

C/O CNS PHARMACEUTICALS, INC

100 WEST LOOP SOUTH, SUITE 900

(Street)

HOUSTON TX 77027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CNS Pharmaceuticals, Inc. [ CNSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$12.48	11/17/2025(1)		A		1,517		(2)	11/17/2035	Common Stock	1,517	$0(3)	1,517	D

Explanation of Responses:

1. The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").

2. The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.

3. Issued in connection with the reporting person's employment with the Company.

	/s/ Christopher Downs, Attorney-in-fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CNS Pharmaceuticals (CNSP) report in this Form 4 filing?

The filing reports that a director of CNS Pharmaceuticals, Inc. received a grant of stock options to purchase the company’s common stock, documented in Table II as a derivative security.

How many CNS Pharmaceuticals stock options were granted and at what exercise price?

The director received an option to purchase 1,517 shares of common stock at an exercise price of $12.48 per share.

When do the CNSP stock options vest for the reporting person?

The options vest in four equal quarterly installments starting on the Shareholder Approval Date, which is November 17, 2025, and each vesting is subject to the reporting person’s continued employment on the relevant vesting date.

What is the expiration date of the CNS Pharmaceuticals stock options reported?

The options expire on November 17, 2035, as shown in the expiration date column of Table II.

Was shareholder approval required for this CNSP stock option grant?

Yes. The option grant was approved by the compensation committee on June 6, 2025, subject to shareholder approval of the stock option plan. Shareholders approved the plan at the annual meeting on November 17, 2025, designated as the Shareholder Approval Date.

How many CNSP derivative securities does the reporting person own after this transaction?

Following the reported transaction, the reporting person beneficially owns 1,517 derivative securities directly, corresponding to the stock option grant.

Why were these CNS Pharmaceuticals options issued to the reporting person?

According to the explanation of responses, the options were issued in connection with the reporting person’s employment with the company.